Bacterial Signature, Digestive Neuroendocrine Tumor, Fecal Microbiota
Conditions
Brief summary
Incidence of digestive neuroendocrine tumors are increasing. Analysis of individual microbiota is a way to explore new neoplastic mechanisms, tumor identification and therapeutic orientations. This prospective pilot study aims to describe fecal bacterial phylogeny of patients with digestive neuroendocrine tumor. Bacterial genomic signature will be recorded at initiation of Lanreotide treatment in naive patient with digestive neuroendocrine tumor (pancreas or small intestine), metastatic or locally advanced, as well as after one year follow up.
Interventions
BIOLOGICALBiological sampling
Blood sample (5mL) for metabolomic dosage and Fecal sample for ARN16s sequencing
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years old or older * naive patient with digestive neuroendocrine tumor (pancreas (cytology or histology per endoscopy or on surgical specimen) or small intestine), secreting or not, initiating a extended release Lanreotide treatment * registered with a social security scheme
Exclusion criteria
* medical contraindication to somatostatine analogs use * history of extended release somatostatine analogs treatment * antibiotic use or colonoscopic purge in the last 3 weeks preceding fecal sample * pregnant or breastfeeding women * person requiring tutorship, guardianship, or person legally protected
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| bacterial genomic signature | Baseline visit | bacterial genomic signature by fecal ARN16S analysis at enrollment |
Contacts
Primary ContactIRADJ SOBHANI, MD-PHD
Outcome results
None listed